In our January issue of Pharmaceutical Executive
FEATURES
Cover Story
Feel the Heat: Pharm Exec’s 2016 Industry Forecast
Casey McDonald, Julian Upton
With daily headers on the high cost of drugs and constant agitation by candidates on either side of the US election, the industry is going to be tested by regulators, patients, and payers with the high expectations commensurate with drug innovation’s status as a “public good.” Can it reclaim a semblance of public approval by focusing on innovation and a fresh, patient-first message? |
From the Editor
A Biopharma Market in Flux
William Looney
Pharm Exec Editor-in-Chief William Looney offers his take on the opportunities, threats, and other big issues facing the industry in the new year. |
Profile
Ferring: The Quiet Company
William Looney
Ferring Pharmaceuticals' Michel Pettigrew talks to Pharm Exec about finding new medical uses for peptide hormones and the company's ambitions to scale up globally by applying cutting-edge research at all stages of the product life cycle. |
Regulatory
Is the Hatch-Waxman System Broken?
Traci Medford-Rosow and Peter C. Richardson.
While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed, write Traci Medford-Rosow and Peter C. Richardson. |
 |
ALSO IN THIS ISSUE
Feel the Earth Move Under Your Brand?
Al Topin
The “seven significants” for brand planning in 2016 that pose the best chance for stable footing amid the seismic state of today’s ever-changing healthcare landscape.
Rough Road Ahead for Innovation
Jill Wechsler
The continuing attack on industry pricing and marketing jeopardizes coverage, R&D.
FDA Drug Approvals 2015
Casey McDonald
Cures remain elusive, but regulators and industry are building ties that bind.
|
|
| |
| WEBCASTS |
| New Tufts CSDD Research: Industry Adoption of eClinical Solutions and CDISC Standards
|
| The Growing Aging Consumer Population – Living Longer, Living Smarter |
Engineer Your Business to Win in the Mobile Selling Moment
|
| |
